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New developments in clinical practice guidelines
During the last four years revised clinical practice guidelines have 
been published by the major nutritional societies: The American 
Society of Enteral and Parenteral Nutrition (ASPEN),1 the European 
Society for Clinical Nutrition and Metabolism (ESPEN)2–11 and the 
Canadian Critical Care Clinical Practice Guidelines Committee 
(CCPG)12 with latest updates from www.criticalcarenutrition.com.
These guidelines agree on most points concerning the nutritional 
support of critical ill patients and will be outlined in a short form. Any 
discrepancies will be highlighted. This outline follows the structure 
of the most recent ASPEN guideline.1 Due considerations relating to 
special diagnoses have not been incorporated in this paper.
Enteral nutrition
Which patient
All: Enteral nutrition (EN) is the preferred form of nutrition support in 
the critical ill patient who is unable to maintain volitional intake. 
ESPEN: It should be given to all patients who are not expected to be 
on a full oral diet within 3 days.
Timing of enteral nutrition
All: EN should be started within the first 24–48 hours following 
admission.
Route of enteral feeding
All: Either gastric or small bowel feeding is acceptable in the ICU 
setting. Critically ill patients should be fed via an enteral access 
tube placed in the small bowel if at high risk for aspiration or 
after showing intolerance to gastric feeding (high gastric residual 
volumes). According to ESPEN, jejunal feeding is likely to be the best 
option when it can be easily implemented (post abdominal trauma or 
elective abdominal surgery). 
CCPG: The routine use of small bowel feedings is recommended in 
units where obtaining small bowel access is feasible.
Dosage of enteral feeding
ASPEN: The feedings should be advanced toward the patient’s goal 
over the next 48–72 hours. Energy requirements may be calculated 
by predictive equations or measured by indirect calorimetry. 
Efforts to provide > 50%–65% of goal energy should be made in 
order to achieve the clinical benefit of EN over the first week of 
hospitalisation. 
ESPEN: No general amount can be recommended as EN therapy has 
to be adjusted according to the progression/course of the disease 
and to gut tolerance. During the acute and initial phase of critical 
illness an exogenous energy supply in excess of 20–25 kcal/kg 
BW/day may be associated with a less favourable outcome. During 
recovery (anabolic flow phase), the aim should be to provide 25–30 
total kcal/kg BW/day.
•	 Controversy:
 ASPEN/CCPG: If unable to meet energy requirements (100% 
of target goal energy) after 7–10 days by the enteral route 
alone, consider initiating supplemental parenteral nutrition (PN). 
Initiating supplemental PN prior to this 7–10 day period in the 
patient already receiving EN does not improve outcome and may 
be detrimental to the patient. 
 ESPEN: All patients who do not meet their nutritional needs after 
2 days should receive supplemental PN.
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Protein requirements
ASPEN: In patients with body mass index (BMI) < 30, protein 
requirements should be in the range of 1.2–2.0 g/kg actual body 
weight per day, and may likely be even higher in thermally injured or 
multi-trauma patients. 
Obese patients
ASPEN: In the critically ill obese patient, permissive underfeeding 
or hypocaloric feeding with EN is recommended. For all classes of 
obesity where BMI is > 30, the goal of the EN regimen should not 
exceed 60%–70% of target energy requirements or 11–14 kcal/kg 
actual body weight per day (or 22–25 kcal/kg ideal body weight per 
day). Protein should be provided in a range ≥ 2.0 g/kg ideal body 
weight per day for Class I and II obese patients (BMI 30–40), and 
≥ 2.5 g/kg ideal body weight per day for Class III obese patients 
(BMI ≥ 40). 
Haemodynamically unstable patients
ASPEN: In the setting of haemodynamic compromise (patients 
requiring significant haemodynamic support including high dose 
catecholamine agents, alone or in combination with large volume 
fluid or blood product resuscitation to maintain cellular perfusion), 
EN should be withheld until the patient is fully resuscitated 
and/or stable. 
Monitoring tolerance and adequacy
ASPEN: In the ICU setting, evidence of bowel motility (resolution of 
clinical ileus) is not required in order to initiate EN in the ICU. In the 
ICU patient population, neither the presence nor absence of bowel 
sounds nor evidence of passage of flatus and stool is required for 
the initiation of enteral feeding. 
Patients should be monitored for tolerance of EN (determined by 
patient complaints of pain and/or distention, physical exam, passage 
of flatus and stool, abdominal radiographs). Inappropriate cessation 
of EN should be avoided. Holding EN for gastric residual volumes 
< 500 mL in the absence of other signs of intolerance should be 
avoided. 
ESPEN/CCPG: IV administration of metoclopramide or erythromycin 
should be considered in patients with intolerance to enteral feeding 
e.g. with high gastric residuals.
ASPEN/CCPG: Use of enteral feeding protocols increase the likelihood 
of overall attainment of percentage of goal energy provided and 
should be implemented. 
ASPEN: Patients placed on EN should be assessed for risk of 
aspiration. Steps to reduce risk of aspiration should be employed. 
 In all intubated ICU patients receiving EN, the head of the bed 
should be elevated 30°–45°. Use of chlorhexidine mouthwash 
twice a day should be considered to reduce risk of ventilator-
associated pneumonia. Blue food colouring and glucose oxidase 
strips, as surrogate markers for aspiration, should not be used 
in the critical care setting.
ASPEN: Development of diarrhoea associated with enteral tube 
feedings warrants further evaluation for aetiology. If there is evidence 
of diarrhoea, soluble fibre containing or small peptide formulations 
may be utilised. 
Immune-modulating enteral formulations
ASPEN/ESPEN: Immune-modulating enteral formulations 
(supplemented with agents such as arginine, glutamine, nucleic acid, 
ω-3 fatty acids, and antioxidants) should be used for the appropriate 
patient population (major elective surgery, trauma, burns, head and 
neck cancer, and critically ill patients on mechanical ventilation), 
with caution in patients with severe sepsis. ICU patients not meeting 
criteria for immune-modulating formulations should receive standard 
enteral formulations. 
To receive optimal therapeutic benefit from the immune-modulating 
formulations, at least 50%–65% of goal energy requirements should 
be delivered daily. 
CCPG: Based on 4 level 1 (A) studies and 17 level 2 (B) studies, we 
recommend that diets supplemented with arginine and other select 
nutrients not be used for critically ill patients.
ALL: Patients with ARDS and severe acute lung injury (ALI) 
should be placed on an enteral formulation characterised by an 




ASPEN: Administration of probiotic agents has been shown to 
improve outcome (most consistently by decreasing infection) in 
specific critically ill patient populations involving transplantation, 
major abdominal surgery, and severe trauma. No 
recommendation can currently be made for use of probiotics in 
the general ICU population due to a lack of consistent outcome 
effect. It appears that each probiotic species may have different 
effects and variable impact on patient outcome, making it 
difficult to make broad categorical recommendations. Similarly, 
no recommendation can currently be made for use of probiotics 
in patients with severe acute necrotising pancreatitis, based on 
the disparity of evidence in the literature and the heterogeneity 
of the bacterial strains utilised. 
CCPG: There are insufficient data to make a recommendation 
on the use of prebiotics/probiotics/synbiotics in critically ill 
patients.
Antioxidant	vitamins	and	selenium
ASPEN/CCPG: A combination of antioxidant vitamins and trace 
minerals (specifically including selenium) should be provided to all 
critically ill patients receiving specialised nutrition therapy.
There are insufficient data to make a recommendation regarding IV/
PN selenium supplementation alone, or in combination with other 
antioxidants, in critically ill patients.
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Glutamine (enteral)
All: The addition of enteral glutamine to an EN regimen (not already 
containing supplemental glutamine) should be considered in 
thermally injured, trauma, and mixed ICU patients.
Soluble fibre
ASPEN: Soluble fibre may be beneficial for the fully resuscitated, 
haemodynamically stable critically ill patient receiving EN who 
develops diarrhoea. Insoluble fibre should be avoided in all critically 
ill patients. Both soluble and insoluble fibre should be avoided in 
patients at high risk for bowel ischaemia or severe dysmotility.
CCPG: There are insufficient data to support the routine use of 




ASPEN: A critically ill ICU patient may be an appropriate candidate 
for PN under certain circumstances: (i) The patient is well nourished 
prior to admission, but if after 7 days of hospitalisation EN has not 
been feasible or target energy goal has not been met consistently 
by EN alone, (ii) On admission, the patient is malnourished and 
EN is not feasible, (iii) A major surgical procedure is planned, the 
preoperative assessment indicates that EN is not feasible through 
the perioperative period, and the patient is malnourished.
ESPEN: All patients who are not expected to be on normal 
nutrition within 3 days should receive PN within 24– 48 h, if EN is 
contraindicated or if patients cannot tolerate EN. 
Patients without malnutrition
•	 Controversy: 
ASPEN: If early EN is not feasible or available the first 7 days 
following admission to the ICU, no nutrition support therapy (i.e. 
standard therapy) should be provided. In the patient who was 
previously healthy prior to critical illness with no evidence of 
protein-energy malnutrition, use of PN should be reserved and 
initiated only after the first 7 days of hospitalisation (when EN is 
not available).  
ESPEN: In patients who tolerate EN and can be fed 
approximately to the target energy values no additional PN 
should be given. In patients who cannot be fed sufficient 
enterally the deficit should be supplemented parenterally. 
In patients intolerant to EN, PN may be proposed at a level 
equal to but not exceeding the nutritional needs of the patient. 
Overfeeding should be avoided.
Patients with malnutrition
ASPEN: If there is evidence of protein-energy malnutrition on 
admission and EN is not feasible, it is appropriate to initiate PN as 
soon as possible following admission and adequate resuscitation.
ESPEN: Patients with a severe undernutrition should receive EN up 
25–30 total kcal/kg BW/day. If these target energy values are not 
reached, supplementary PN should be given.
Central or peripheral access
ESPEN: A central venous access device is often required to administer 
the high osmolarity PN mixture designed to cover the nutritional 
needs fully. Peripheral venous access devices may be considered 
for low osmolarity (< 850 mOsmol/L) mixtures designed to cover a 
proportion of the nutritional needs and to mitigate negative energy 
balance.
All-in-on bags
ESPEN: PN admixtures should be administered as a complete all-
in-one bag.
Dosing
ASPEN: In all ICU patients receiving PN, mild permissive underfeeding 
should be considered at least initially. Once energy requirements are 
determined, 80% of these requirements should serve as the ultimate 
energy goal or dose of parenteral feeding. Eventually, as the patient 
stabilises, PN may be increased to meet energy requirements. For 
obese patients (BMI ≥ 30), the dose of PN with regard to protein and 
energy provision should follow the same recommendations given for 
EN. 
ESPEN: During acute illness, the aim should be to provide energy 
as close as possible to the measured energy expenditure in order 
to decrease negative energy balance. In the absence of indirect 
calorimetry, ICU patients should receive 25 kcal/kg/day increasing 
to the energy target over the next 2–3 days.
CCPG: In critically ill patients who are not malnourished, are tolerating 
some EN, or when PN is indicated for short term use (< 10 days), low 
dose PN should be considered. There are insufficient data to make 
recommendations about the use of low dose PN in the following 
patients: those requiring PN for long term (> 10 days), obese critically 
ill patients, and malnourished critically ill patients. Practitioners will 
have to weigh the safety and benefits of low dose PN on an individual 
case-by-case basis in these latter patient populations.
Parenteral nutrition supplementary to enteral nutrition
•	 Controversy:
 ASPEN: A critically ill ICU patient may be an appropriate 
candidate for PN under certain circumstances:
 (i) The patient is well nourished prior to admission, but after 
7 days of hospitalisation, EN has not been feasible or target 
energy goal has not been met consistently by EN alone. 
 ESPEN: All patients receiving less than their targeted enteral 
feeding after 2 days should be considered for supplementary 
PN.
 CCPG: We recommend that PN not be started at the same time 
as enteral nutrition. In the patient who is not tolerating adequate 
enteral nutrition, there are insufficient data to put forward a 
recommendation about when PN should be initiated. 
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Carbohydrates
ESPEN: The minimal amount of carbohydrate required is about 
2 g/kg of glucose per day.
Glucose control
ASPEN: A protocol should be in place to promote moderately strict 
control of serum glucose when providing nutrition support therapy. 
A range of 6– 8 mg/dL may be most appropriate.
ESPEN: Hyperglycaemia (glucose > 10 mmol/L) contributes to death 
in the critically ill patient and should also be avoided to prevent 
infectious complications. Reductions and increases in mortality rates 
have been reported in ICU patients when blood glucose is maintained 
between 4.5 and 6.1 mmol/L. No unequivocal recommendation has 
been reported in ICU patients when blood glucose is maintained. 
There is a higher incidence of severe hypoglycaemia in patients 
treated to the tighter limits.
Canadian Guidelines: We recommend that hyperglycaemia (blood 
sugars > 10 mmol/L) be avoided in all critically ill patients. Based on 
the NICE-SUGAR study and a recent meta-analysis, we recommend 
a blood glucose target of around 8.0 mmol/L (or 7–9 mmol/L), rather 
than a more stringent target range (4.4 to 6.1 mmol/L) or a more 
liberal target range (10 to 11.1 mmol/L).
Lipids
ASPEN/Canada: In the fi rst week of hospitalisation in the ICU, when 
PN is required and EN is not feasible, patients should be given a PN 
formulation without soy-based lipids.
ESPEN: Lipid emulsions should be an integral part of PN for energy 
and to ensure essential fatty acid provision in long-term ICU patients. 
The tolerance of mixed LCT/MCT lipid emulsions in standard use 
is suffi ciently documented. Several studies have shown specifi c 
clinical advantages over soybean LCT alone but require confi rmation 
by prospective controlled studies. Olive oil-based PN is well tolerated 
in critically ill patients. Addition of EPA and DHA to lipid emulsions 
has demonstrable effects on cell membranes and infl ammatory 
processes. Fish oil-enriched lipid emulsions probably decrease 
length of stay in critically ill patients. Intravenous lipid emulsions 
(LCT, MCT or mixed emulsions) can be administered safely at a rate 
of 0.7 g/kg up to 1.5 g/kg over 12–24 h.
Amino acids
ESPEN: When PN is indicated, a balanced amino acid mixture should 
be infused at approximately 1.3–1.5 g/kg ideal body weight per day 
in conjunction with an adequate energy supply.
Canadian Guidelines: In critically ill patients who are receiving PN, 
there are insuffi cient data to make a recommendation regarding the 
use of branched chain amino acids.
Glutamine (parenteral)
All: When PN is indicated in ICU patients the amino acid solution 
should contain 0.2–0.4 g/kg/day of L-glutamine (e.g. 0.3–0.6 g/kg/
day alanyl-glutamine dipeptide).
Micronutrients
All: All PN prescriptions should include a daily dose of multivitamins 
and of trace elements.
Efforts to initiate enteral feeding
ASPEN: In patients stabilised on PN, periodically repeated efforts 
should be made to initiate EN. As tolerance improves and the volume 
of EN energy delivered increases, the amount of PN energy supplied 
should be reduced. PN should not be terminated until ≥ 60% of target 
energy requirements are being delivered by the enteral route. 
References
1.  McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of 
Nutrition Support Therapy in the Adult Critically Ill Patient:: Society of Critical Care Medicine (SCCM) 
and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 
2009;33(3):277–316.
2.  Kreymann KG, Berger MM, Deutz NE, et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin 
Nutr 2006;25(2):210–223.
3.  Singer P, Berger MM, Van den Berghe G, et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. 
Clin Nutr 2009;28:387–400.
4.  Weimann A, Braga M, Harsanyi L, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ 
transplantation. Clin Nutr 2006;25(2):224–244.
5.  Braga M, Ljungqvist O, Soeters P, Fearon K, Weimann A, Bozzetti F. ESPEN Guidelines on Parenteral 
Nutrition: surgery. Clin Nutr 2009;28:378–386.
6.  Anker SD, John M, Pedersen PU, et al. ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. 
Clin Nutr 2006;25(2):311–318.
7.  Anker SD, Laviano A, Filippatos G, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and 
pneumology. Clin Nutr 2009;28:455–460.
8.  Cano N, Fiaccadori E, Tesinsky P, et al. ESPEN Guidelines on Enteral Nutrition: Adult renal failure. Clin Nutr 
2006;25(2):295–310.
9.  Cano NJ, Aparicio M, Brunori G, et al. ESPEN Guidelines on Parenteral Nutrition: adult renal failure. Clin 
Nutr 2009;28:401–414.
10.  Meier R, Ockenga J, Pertkiewicz M, et al. ESPEN Guidelines on Enteral Nutrition: Pancreas. Clin Nutr 
2006;25(2):275–284.
11.  Gianotti L, Meier R, Lobo DN, et al. ESPEN Guidelines on Parenteral Nutrition: pancreas. Clin Nutr 
2009;28:428–435.
12.  Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P. Canadian clinical practice guidelines for 
nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 
2003;27(5):355–373.
